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“If your experiment needs statistics, you ought to have done a better experiment.” 
- Ernest Rutherford.  
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Summary 
Patients with end-stage kidney disease (ESKD) have a high risk of infective diseases in part as a 
consequence of renal replacement therapy (RRT) modalities. 
This dissertation aimed to investigate incidence and risk factors of infective endocarditis (IE) and 
Staphylococcus aureus bacteremia (SAB) in Danish ESKD patients by using nationwide Danish 
administrative registries. 
Paper I investigated the incidence and risk factors of IE in different modalities of RRT during 1996-
2012 in 10,612 ESKD patients. The main finding was an increased risk of IE in patients receiving 
hemodialysis compared with peritoneal dialysis patients. Central venous catheters (CVC) carried 
the highest risk in patients receiving hemodialysis. The risk of IE in patients with CVC (cuffed and 
uncuffed) was comparable. The initial 6 months of RRT carried a high risk of IE.  
Paper II evaluated the mortality rate and cause of death in hemodialysis- and non-ESKD patients 
with Staphylococcus (S.) aureus endocarditis. The major finding was a similar in-hospital mortality 
rate in hemodialysis- compared with non-ESKD patients, whereas the mortality rate at one-year 
follow-up was higher in hemodialysis- compared with non-ESKD patients. The risk of all-cause- and 
cardiovascular mortality in patients receiving hemodialysis exceeded the risk in non-ESKD patients 
at more than 70 days and 81 days after admission with S. aureus endocarditis, respectively. 
Paper III investigated the risk and incidence of SAB by hemodialysis vascular access types from 
1996-2011 in 9997 ESKD patients. The primary finding was an increased risk of SAB in patients 
receiving hemodialysis compared with those receiving peritoneal dialysis. The risk of SAB was 
markedly increased in patients receiving hemodialysis with CVC. The SAB risk did not differ in 
cuffed- and uncuffed CVC. The initial 90 days of RRT with CVC carried the highest risk of SAB 
followed by arteriovenous fistula.  
The main results of this thesis outline the high risk of IE and SAB in patients with ESKD. The 
findings emphasize the importance of increased awareness among health professionals of IE and 
SAB especially in the initial period of RRT. 
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Introduction 
End-stage kidney disease and renal replacement therapy 
End-stage kidney disease (ESKD) is the final stage of chronic kidney disease and is defined as a GFR 
below 15 ml/min per 1.73 m2. At this stage, the renal capacity is insufficient to maintain the 
functions of the kidney. The main renal functions include the regulation of water-, acid- and 
electrolyte balance, blood pressure and bone mineral homeostasis. Additionally, the kidney 
contributes to the maintenance of the hematopoietic homeostasis by producing erythropoietin. 
The imbalance in these regulative mechanisms emerges at GFR below 60 ml/min per 1.73 m2 and 
continues to deteriorate parallel to the decline in kidney function (1). At the last stage of chronic 
kidney disease, the disorders are severe and require renal replacement therapy (RRT) to continue 
life. 
Diabetes is the predominant known reason to ESKD in Denmark followed by vascular and 
hypertensive causes. The proportion of patients progressing towards ESKD with diabetes as the 
underlying cause was 26% in 2016. Hypertensive and vascular causes accounted for 16%. Patients 
with an unknown etiology of ESKD attribute as well to a major part of emerging ESKD cases. The 
proportion has been stable over the last decade and represented 17% in 2016 (2). 
In Denmark, patients with ESKD are provided government-supported RRT, which includes 
hemodialysis (HD), peritoneal dialysis (PD), pre-emptive kidney transplantation and kidney 
transplantation (KT) after initiation of dialysis. The decision to initiate RRT relies on the physician 
and is based on individual evaluation of the ESKD patient. The Danish ESKD population of RRT 
recipients consisted of 5363 patients in 2016. Of these, 2566 (48%) were in maintenance dialysis 
and 2797 (52%) had a functioning KT. The annual number of chronic kidney disease patients 
progressing towards ESKD requiring RRT was 703 in 2016. This proportion has been stable over the 
last decade (2). The majority of these patients received HD as the initial RRT modality, followed by 
PD and pre-emptive kidney transplantation. In most cases, the establishment of a vascular access 
is easier to facilitate and apply than a peritoneal catheter. The availability of kidney donors, pre-
emptive, is sparse and consequently only a limited number of patients are transplanted pre-
emptively.  
9 
 
ESKD patients receiving RRT are subject to change of RRT modality during the treatment course. 
These changes are either based on continuously individual evaluation by physicians, a 
consequence of complications second to the respective RRT modality or a sudden opportunity of 
receiving a KT. HD is initiated either by a cuffed central venous catheter (CVC), an uncuffed CVC, 
an arteriovenous fistula or an arteriovenous graft. The uncuffed CVC is a temporary vascular 
access and serves primarily as a bridge therapy to cuffed CVC at immediate initiation of HD. The 
insertion of an uncuffed CVC is easier to facilitate than a cuffed CVC, which requires expertise. The 
cuffed CVC is a bridge device to maturation of arteriovenous fistula or a final option in patients 
with no possibilities of establishing an arteriovenous fistula. The CVCs are associated with certain 
complications, which result in replacement of the CVC or switch in treatment modality primarily 
from cuffed CVC to uncuffed CVC in order to maintain the vascular access. The complications 
related to CVC use include the development of infection, thrombosis and vascular stenosis (3;4).  
The arteriovenous fistula is the vascular access of choice for HD. It requires a surgical procedure 
and consists of an end-to-end arteriovenous anastomosis. The maturation time of an 
arteriovenous fistula is two to four months and necessitates in meanwhile bridging with CVC if 
immediate HD is needed. The arteriovenous fistula may be subject to maturation failure, which 
prolongs the period with CVC use. Infection, thrombosis and steal syndrome are few of the related 
complications to arteriovenous fistula, which result in temporary use of CVC (5).The arteriovenous 
graft is a prosthetic vascular access applied in patients with fragile vessels. This vascular access 
type is complicated with a high frequency of infection, thrombosis and stenosis compared with 
arteriovenous fistula (6). 
PD treatment is facilitated by a catheter inserted into the peritoneal cavity. The catheter is ideally 
applicable for dialysis two to four weeks after insertion and HD may be a temporary necessity. CVC 
is easy to facilitate and is commonly applied as the temporary vascular access. A major cause of 
technique failure that can occur during PD treatment is peritonitis, which can lead to temporary 
switch to HD with CVC as vascular access (7;8). Pleuroperitoneal communication and 
encapsulating peritoneal sclerosis are few of the rare issues associated to PD treatment, which 
result in temporary and permanent switch to HD, respectively (9;10). 
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KT patients are at risk of graft failure. The most common cause of graft loss is patient death 
followed by chronic allograft nephropathy in KT patients. Few less frequent causes are graft 
rejection, glomerulonephritis and BK nephropathy (11). Graft loss necessitates institution of RRT 
with either HD or PD. 
Hence, shifts in modality of RRT is common within the ESKD population, and many of these shifts 
are acute or subacute leaving HD with CVC, as the rescue treatment. 
     
Infection and immune dysfunction         
Infective diseases are the second leading cause of death in patients with ESKD receiving RRT 
(12;13). The proportion of death caused by infective diseases was 11% in a large European 
population of ESKD patients treated with RRT (13). Access-related infection, pneumonia and 
urinary tract infection remain the most common infections in patients on dialysis (14). The 
predominant infections in KT recipients are urinary tract infection followed by pneumonia (15). As 
the renal disease progresses and the renal function declines, various solutes accumulate in the 
body. These retained solutes are called uremic toxins and are considered to contribute to immune 
dysfunction (16). Patients with ESKD receiving RRT are disposed to infections and the impared 
immune system second to uremic toxins is a contributing factor. 
 
Cardiovascular disease 
Cardiovascular disease remains the leading cause of death in patients with ESKD and responsible 
for 24% of deaths in a recent European study with ESKD patients (13). The frequency of vascular 
calcification in patients with ESKD is high and is presumed to contribute to cardiovascular disease 
(17;18). Risk factors of vascular calcification include dialysis vintage, diabetes, aging and mineral 
disorders (19). In addition to cardiovascular disease, chronic kidney disease patients are at 
increased risk of contracting stroke and developing peripheral artery diseases as the renal disease 
progresses (20;21). Moreover, heart valve diseases are common in dialysis patients with 
thickening and calcification of the valves (22;23). The most severely affected heart valves include 
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the aortic- and mitral valves (22;23). The valvular degenerations evolve at younger age in dialysis 
patients than in those without chronic kidney disease (24;25). Duration of dialysis treatment, age 
and calcium-phosphate disorders may in part explain the deformation of the heart valves (23;24). 
The gradual calcification of the aortic- and mitral valves may render these susceptible to the 
development of infective endocarditis (IE) (22;24). 
 
Infective endocarditis  
IE is an infection with serious morbidity and mortality with an incidence rate of 8-10/100,000 
person-years in the general Danish population (26-29). In Denmark, the most common 
microbiological causes of IE are streptococci- and staphylococci species followed by enterococci 
species (26). Stroke, heart failure and metastatic infections are serious and common complications 
of IE (29).  The IE diagnosis is confirmed with imaging techniques as echocardiography. 
Transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) are both 
techniques applied in the diagnosis of IE. However, TEE is superior to TTE in detecting IE. The 
sensitivity of identifying vegetations on native valves is 96% for TEE and 70% for TTE. Moreover, 
TEE is superior to TTE to rule out small vegetations on the valves and paravalvular pathology (30).      
The incidence rate of IE is high in dialysis patients. The incidence rate of IE in a US ESKD population 
was 483/100,000 person-years in HD and 248/100,000 person-years in PD (31). The most frequent 
cause of IE in HD is S. aureus followed by coagulase-negative staphylococci-, enterococci- and 
streptococci species (32-36). The risk of IE in KT compared with PD is unexplored.  
Existing data on the occurrence of IE, classified by HD vascular access, are limited to the vascular 
access types with IE cases of 17-150 patients (32-40). Thus, incidence rates and risk factors of IE 
related to each vascular access of HD with time-updated RRT modalities in patients with ESKD 
remain to be resolved.      
IE remains a contributor to mortality in HD patients (31-38;41-43). Depending on the study 
population, the in-hospital mortality rates subsequent to IE ranged from 14%-52% in HD patients 
(32;36;37;43). The one-year mortality rate was 56% in a single center study in 32 cases of IE 
among 2239 HD patients (33). Septic embolism and mitral valve disease are recognized as 
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mortality risk factors (35). Neither of these aforementioned studies determined cause of death 
and mortality risk factors of S. aureus endocarditis in a nationwide population of HD patients 
compared with a non-ESKD population. 
 
Staphylococcus aureus bacteremia 
The incidence rate of Staphylococcus aureus bacteremia (SAB) in the Danish general population 
was 0.035/100 person-years in 2015 (44). The incidence rate of SAB has been increasing steadily 
during the past several decades. The recent rise in SAB cases has been attributed to the elderly 
population. SAB contributes to severe secondary infective complications. In Denmark, the most 
frequent infections second to SAB include IE followed by spondylitis and prosthetic infections (44).  
Bacteremia is a complication in patients with ESKD receiving RRT. The most prevalent isolated 
microorganisms in Danish PD patients were Escherichia coli and S. aureus. Peritonitis followed by 
urinary tract- and respiratory tract infections were the most common infections in these PD 
patients (45). The distribution of bacteria in relation to bacteremia in patients with KT differs from 
dialysis patients and correlate with the most prominent location of infection. The urinary tract 
system is the most frequent location of infection in patients with KT and as a result of this; 
Escherichia coli and Klebsiella pneumonia are the most common isolated microorganisms 
(15;46;47).      
In patients with HD, bacteremia is a consequence of repeated access to the vascular system along 
with uremia related suppression of the immune system and the acquired local granulocyt defect at 
the access site (16;48). SAB is frequent in HD patients and leads to infections with severe 
morbidity and mortality (49-63). Although, the CVCs (cuffed and uncuffed) are well-established 
causes of bacteremia (61;64), the incidence rate and risk factors of SAB, classified according to 
each HD vascular access has not been investigated with time-updated HD vascular access.  
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Objectives 
The present thesis focused on the analyses of IE, SAB and outcomes in ESKD patients with 
established RRT with the following objectives: 
Paper 1 
To examine the incidence rate and risk factors of IE in a nationwide ESKD population treated with 
RRT. 
Hypothesis: The risk of IE is increased in HD compared with either PD or KT. 
Paper 2 
To examine the mortality risk and cause of death subsequent to S. aureus endocarditis in a 
nationwide population of HD patients compared with a non-ESKD population. 
Hypothesis: The long-term mortality rate is higher in the HD population with S. aureus 
endocarditis compared with the non-ESKD population with S. aureus endocarditis. 
Paper 3 
To examine the incidence rate and risk factors of SAB in ESKD patients receiving RRT with focus on 
the type of HD vascular access. 
Hypothesis: The incidence rate of SAB is higher in patients with CVC as HD vascular access than 
other RRT modalities.   
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Materials and methods 
Denmark possesses nationwide administrative registries that provide a variety of variables 
pertaining health care status at an individual level. The Danish Civil Registration System assigns 
each residence at birth or immigration a unique personal identification number that is used in all 
nationwide registries and allows linkage between these registries at an individual level (65). The 
studies in this thesis used a number of these registries.  
Data sources 
1) The Danish National Patient Registry was established in 1978 and holds information on 
diagnoses and surgical procedural codes. Each inpatient admission and outpatient 
consultation is at discharge or end of appointment registered with one primary and one or 
more secondary diagnoses according to the International Classification of Diseases revision 
8th (ICD-8), replaced by ICD-10 from 1994 onwards (66). The codes used to assess Charlson 
comorbidities are considered valid (67). The surgical procedural codes are registered in 
accordance to the Nordic-Medical Statistical Committee’s Classification of Surgical 
Procedures (NCSP). 
2) The Register of Medicinal Product Statistics contains information on every purchased 
prescription since 1995 on date of purchase, content and amount coded by the Anatomical 
Therapeutic Classification system (ATC). Redeemed prescriptions are partially reimbursed 
and therefore an incentive to record purchased pharmacotherapy at individual level is 
present. The data quality of the registry is considered high (68).  
3) The Danish National Registry on Regular Dialysis and Transplantation holds information on 
all Danish ESKD patients in RRT (HD, PD and KT) including change in treatment modality, 
since 1990. ESKD patients are registered after at least three months in RRT. The registry 
has a completeness of more than 97% compared with the Danish National Patient Registry 
as reference standard (69).  
4) The Danish Registry of Cause of Death includes information on each occurring death in 
Denmark on individual level since 1970, coded according to the ICD-10 from 1994 onwards 
(70). 
5) The Danish Civil Registration System was established in 1968 and includes information on 
birth date, gender and vital status on individual level (65). 
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6) The East Danish Database on Endocarditis enrolled patients diagnosed with IE 
prospectively from October 1st, 2002 to December 31st, 2012 at two referral tertiary heart 
centers (Rigshospitalet and Gentofte Hospital). The diagnosis of IE was based on the 
revised Duke criteria (71). The database contains more than 250 variables (e.g. 
microbiology, echocardiography, and clinical data) (72).  
7) The SAB Database is nationwide and located at Statens Serum Institut. This database was 
established in 1956 and contains information on more than 94% of SAB cases in Denmark, 
referred from all Danish Departments of Microbiology (44). 
8) The Departments of Microbiology provided information on the causative microorganism of 
IE.  
 
Ethics and data protection 
The studies were approved by the Danish Data Protection Agency (ref. 2007-58-0015 / internal ref. 
GEH-2014-015 I-suite no. 02733). Ethical approval is not required for registry based studies in 
Denmark. The data is encrypted and accessed via a secured server located at Statistics Denmark. 
 
Study population 
Paper I & Paper III 
From The Danish National Registry on Regular Dialysis and Transplantation, we identified all ESKD 
patients initiating and changing RRT (HD, PD, pre-emptive KT, KT) between January 1st 1996 and 
December 31st 2012. In paper III, the cohort was only followed until December 31st 2011.  
To allow changes in treatment modalities during follow-up, procedural codes pertaining HD 
vascular access and peritoneal catheter were obtained from The Danish National Patient Registry, 
Table 1. In addition in paper I, procedural codes for heart valve surgery were retrieved, Table 1. 
The Danish National Registry on Regular Dialysis and Transplantation and the procedural codes 
extracted from The Danish National Patient Registry on RRT modalities were merged, enabling 
patients to change treatment modality during follow-up (e.g. patients in PD could change to KT 
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during follow-up and add risk time to more than one RRT modality). Patients receiving RRT with PD 
and HD concurrently before switching to HD permanently were treated as HD patients. These data 
were assessed manually in cooperation with two independent nephrologists. 
From The Danish National Patient Registry, we assessed comorbidities up to 5 years prior to index 
until event of interest, death or study end, whichever came first. The purchase of glucose-lowering 
drug prescriptions obtained from The Register of Medicinal Product Statistics was used as a proxy 
for a diabetes mellitus diagnosis (Appendix I, Supplemental Table I). The ATC codes of glucose-
lowering drugs have been applied as a proxy for the diagnosis of diabetes mellitus in a recent 
study (73).      
Paper II 
We retrospectively identified a HD population from The Danish National Registry on Regular 
Dialysis and Transplantation between January 1st, 1996 and December 31st, 2012 and included 
each patient at the first episode of IE with S. aureus after initiation of RRT. The diagnosis of IE was 
identified in The Danish National Patient Registry with the ICD-10 codes I33 and I38. Data on 
microbiology was collected from Departments of Microbiology. Information on valve involvement 
and echocardiography was obtained from medical records.  
From The East Danish Database on Endocarditis, we identified a non-ESKD population with S. 
aureus endocarditis. Patients receiving temporary HD following acute kidney failure during 
admission were not excluded, Table 1. 
Comorbidities were identified from The Danish National Patient Registry in a period of 5 years 
before inclusion. 
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Table 1. List of procedural codes 
 
*NCSP 
  
Hemodialysis vascular access 
 
 
 
 
 
 
BMBZ51A, BMBZ51B, 
BMBZ51D, BMBZ51F, 
BMBZ61, BMBZ61A, 
BMBZ71, BMBZ71A, KBPL, 
KBPL10, KBPL10A, KBPL20, 
KBPL20A, KBPL30, KBPL30A, 
KBPL99   
  Peritoneal catheter BJFZ45 
  Acute dialysis BFJD00, BJFD01, BJFD02 
  
Heart valve surgery KFG, KFK, KFM, KFJE, KFJF 
 *NCSP  Nordic-Medical Statistical Committee’s Classification of Surgical Procedures  
18 
 
Outcome 
The thesis was based on following end points 
Paper I 
The first episode of IE after initiation of RRT was the end point of interest in paper I (ICD-10 codes 
I33 and I38).  
Paper II 
The main outcome in paper II was all-cause mortality, subdivided into cardiovascular- and non-
cardiovascular death (Appendix II, Supplemental Table III). The cause of death was considered 
cardiovascular, if at least one of the diagnoses on the death certificate were cardiovascular (ICD-10 
I-diagnoses).   
Paper III 
The end point in paper III was first time SAB after initiation of RRT.  
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Statistical analyses 
In all papers, continuous variables were reported as mean±standard deviation. Differences in 
continuous variables and categorical variables were tested with Kruskall-Wallis test and Chi-
squared test, respectively. Fisher’s exact test was applied when expected frequency in the cells 
was <5 in paper II.  
SAS version 9.4 (SAS institute, Cary, NC, USA) was applied for statistical analyses. Two-sided p- 
value <0.05 was considered statistically significant. 
Paper I 
The incidence rate of IE was estimated for the entire cohort of ESKD patients and each RRT 
modality based on number of events divided by risk time added to each respective RRT modality 
/100,000 person-years. The relative time in CVC was calculated based on the proportion of time 
spent in CVC divided by the entire time spent in RRT in time band of one year by calendar year. 
The Cox regression model was used in a time dependent manner to assess the association 
between each RRT modality and the outcome, IE, and to identify independent risk factors. The RRT 
modality was time-updated, allowing patients to change treatment modality during follow-up and 
add risk time to more than one treatment subset. Comorbidity (mitral-, aortic valve disease and 
diabetes) entered this model and was updated as noted. Diabetes was updated as glucose-
lowering drug was purchased.  Furthermore, this model was adjusted for calendar year, which was 
split in bands of five years. Time spent in RRT was added to the model and split in three time 
periods at 183 days- and at 845 days after initiation of RRT, according to the first two quartile 
distribution of outcome. Gender and IE prior to RRT was applied and age was used as the 
underlying time-scale. Interaction was assessed between RRT modalities and the covariates added 
to the model and found valid except from age. Age-stratified analysis was performed to assess the 
interaction.  
Cochrane-Armitage time trend test was used to assess the trend in the incidence of ESKD patients 
and IE across the study period.   
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Paper II 
Cox regression model was applied to examine time from S. aureus endocarditis until death (all-
cause mortality, cardiovascular death and non-cardiovascular death) or study end. The hazard 
ratio between the exposures (HD and non-ESKD) varied over time (violation of proportional hazard 
assumption) and entered therefore the model in categorical time periods of below 20 days, 20-70 
days and at least 71 days for the outcome, all-cause mortality, and in time periods of below 26 
days, 26-81 days and at least 82 days for the outcome, cardiovascular death. These periods 
represented the first- and second quartile distribution of outcome. The model was adjusted for 
gender, age and diabetes mellitus. Time from S. aureus endocarditis to death or study end was 
applied as the underlying time-scale in the model. The cumulative incidences were assessed for 
all-cause mortality and for each of the end points; cardiovascular- and non-cardiovascular death 
accounting for competing risks of death. 
Ten HD patients changed RRT modality during the study period. Sensitivity analyses were 
performed excluding these patients. The hazard ratios and cumulative incidences remained 
unaltered.     
Paper III    
The incidence rate of SAB was calculated for the entire cohort of ESKD patients and for each RRT 
modality. The number of cases in each RRT modality was divided by the time spent in the RRT 
treatment groups. Poisson regression was used to determine the association between the various 
modalities of RRT and SAB. The RRT modalities entered the analysis time-updated, enabling 
patients to change treatment group and add risk time to more than one group during follow-up. 
Age, gender and comorbidity (diabetes mellitus, mitral- and aortic valve disease) were included in 
the model. Comorbidity was split at the time it was noted. Diabetes mellitus was noted at 
redemption of prescription. Age was split in bands of one year and calendar time entered the 
model in time-bands of five years. The time spent in RRT was split in time bands of three periods 
at 90 days- and at >270 days after initiation of RRT. The second split represented the second 
quartile distributed according to outcome. Test for interaction between RRT modalities and the 
covariates were found valid except from time spent in RRT.  Stratified analysis of time spent in RRT 
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was performed to assess the interaction. Moreover, trend test was performed to examine the 
incidence of SAB during the study period.  
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Main results 
Summary of main results and conclusions from the studies are presented in the subsequent 
section of the thesis. For further details, the papers I-III on which the thesis is based, are referred 
in appendix I-III.   
Paper 1 
A total of 10,612 ESKD patients initiated RRT in the period January 1st 1996 to December 31st 2012. 
The initial population comprised 7233 HD patients (68%), 3056 PD patients (29%), and 323 pre-
emptive KT (3%). First time IE during ESKD treatment with RRT occurred in 267 patients across the 
study period, Table 1. The incidence rate of IE was remarkably higher in HD patients than PD- and 
KT patients, Table 1. The incidence rate of IE was highest in patients with CVC (cuffed and 
uncuffed) as vascular accesses in HD, Table 1. The risk of IE was increased in patients receiving HD 
especially with CVC compared with PD patients, Table 1. There was no difference in the risk of IE 
between uncuffed CVC compared with cuffed CVC, HR 1.40 (95% CI 0.89-2.21). The first six months 
in RRT, aortic valve disease and IE prior to RRT were independently associated to IE, Table 1. 
The in-hospital mortality and one-year mortality subsequent to IE and heart valve surgery was 
elevated in HD patients compared with PD- and KT patients, Tables 2 & 3. 
The increase in incident cases of IE during the period 1996 to 2012 in patients with ESKD 
compared with the increase in the incidence of ESKD patients, adjusted for the general population, 
was significant, Figure 1.  
The proportion of time spent in CVC increased across the study period. Patients above 70 years 
comprised a larger percentage of the relative time in CVC, Figure 2. 
In conclusion, we observed an increased risk of IE in HD patient compared with PD patients. The 
risk of IE was in particular increased in HD patients treated with CVC. We identified the first six 
months in RRT, aortic valve disease and IE prior to RRT as independent risk factors of IE.   
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Table 1. Risk factors of infective endocarditis in end-stage kidney disease patients receiving renal 
replacement therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter Number of events 
Unadjusted incidence 
rate/100,000 person-years 
Hazard Ratio                   
(95% Confidence Interval) 
Renal replacement modality    
   
*
Uncuffed CVC 39 3053 14.10 (7.76-25.50) 
   
*
Cuffed CVC 39 2099 10.03 (5.52-18.24) 
    Arteriovenous fistula 138 874 4.59 (2.73-7.73) 
    Arteriovenous graft 1 570 3.19 (0.42-24.26) 
    Unknown hemodialysis access 24 809 3.67 (1.94-6.94) 
    Hemodialysis 241 1092 5.46 (3.28-9.10) 
    Kidney transplant 10 85 0.41 (0.18-0.91) 
    Peritoneal dialysis 16 212 1.00 (reference) 
Renal replacement therapy periods    
    
†
Renal replacement therapy period 1 67 1353 1.89 (1.37-2.60) 
    
†
Renal replacement therapy period 2 67 501 0.80 (0.59-1.10) 
    
†
Renal replacement therapy period 3 133 549 1.00 (reference) 
Comorbidity    
    Diabetes mellitus    
1 102 817 1.12 (0.87-1.45) 
0 165 549 1.00 (reference) 
    
‡
Endocarditis    
1 20 17321 22.24 (13.50-36.62) 
0 247 581 1.00 (reference) 
    Aortic valve disease    
1 41 2139 2.65 (1.68-4.18) 
0 226 556 1.00 (reference) 
    Mitral valve disease    
1 20 1757 1.38 (0.71-2.70) 
0 247 596 1.00 (reference) 
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* CVC central venous catheter 
† Renal replacement period 1: First 183 days in renal replacement period, Renal replacement period 2: 184-845 days in Renal 
replacement period, Renal replacement period 3: >845 days 
‡ Before initiation of renal replacement therapy  
§ Model adjusted for sex, age, diabetes, aortic valve disease, mitral valve disease, previous endocarditis, calendar year, renal 
replacement periods (<183 days-, 184-845 days- and >845 days in renal replacement therapy). 
 
Table 2.  Mortality subsequent to infective endocarditis 
 
 
 
 
 
*Values are given as N (%) 
Table 3. Heart valve surgery and mortality 
                        Heart valve surgery   Mortality 
Renal replacement  
therapy Total 
Aortic 
valve  
Mitral 
valve  
Pulmonic 
valve  
Mitral- and 
aortic valve 
 
In-hospital  
 
 
1-year including 
in-hospital  
Total 31 11 15 1 4  5 (16%) 
 
12 (39%) 
Hemodialysis 28 10 17 1 3  4 (14%) 
 
10 (36%) 
    Cuffed CVC 1 - 1 - -  -  - 
    Uncuffed CVC 7 2 5 - -  -  - 
    Arteriovenous  
fistula 
17 8 7 1 1 
 
-  - 
    Unknown vascular 
access 
3 - 1 - 2 
 
-  - 
Peritoneal dialysis 1 - 1 -   - 
 
1 (100%) 
Kidney transplant 2 1 
 
- 1  1 (50%) 
 
1 (50%) 
 
*Values are given as N (%) 
†CVC central venous catheter 
Renal replacement therapy In-hospital  1-year including in-hospital 
Overall 58 (22%)  135 (51%) 
Hemodialysis 53 (20%)  124 (46%) 
Peritoneal dialysis 4 (2%)  8 (3%) 
Kidney transplant 1 (0.3%)  3 (1%) 
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Figure 1. 
Incidence of Infective Endocarditis and End-stage Renal Disease
Year
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*The p-value refers to the significant increase in incidence cases of IE compared with the increase in incidence of ESKD patients, 
adjusted for the general population.  
Table 3. Relative time in central venous catheter across the study period 1996-2012 
Relative time in Central Venous Catheter
as proportion of overall time in Renal Replacement Therapy 
Years
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*Relative time in CVC as percentage of time in RRT by calendar year 
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Paper 2 
A total number of 121 HD patients with first time IE after initiation of RRT, if S. aureus 
endocarditis, were identified from 8791 patients in HD. From the East Danish database on 
Endocarditis, 190 non-ESKD patients with S. aureus endocarditis were identified among 977 
patients with IE. During admission, 31 non-ESKD patients developed acute kidney failure and 
received temporarily HD. 
The all-cause in-hospital mortality subsequent to S. aureus endocarditis was similar in HD and non-
ESKD patients, whereas the one-year mortality was significantly higher in the HD- compared with 
non-ESKD patient, Table 1. 
After an initial period of similar all-cause mortality, cardiovascular death and non-cardiovascular 
death in HD- and non-ESKD patients, the risk of all-cause mortality and cardiovascular death in HD 
patients exceeded the risk in non-ESKD patients, Figure 1 & 2. 
The risk of all-cause mortality increased significantly in HD patients compared with non-ESKD 
patients >70 days after admission, Figure 3. Age and diabetes mellitus were identified as 
independent risk factors. The cardiovascular risk of death was significantly elevated >81 days after 
admission in HD patients compared with non-ESKD patients, Figure 4. Age and diabetes mellitus 
were associated to cardiovascular death.  
In conclusion, the all-cause in-hospital mortality for S. aureus IE in HD patients is similar to non-
ESKD patients, whereas the one-year mortality is significantly higher in HD patients compared with 
non-ESKD patients. All-cause mortality and cardiovascular death increased significantly in HD 
patients compared with non-ESKD patient more than 70 days and 81 days after admission with S. 
aureus endocarditis, respectively. 
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Table 1. In-hospital- and one-year mortality subsequent to Staphylococcus aureus endocarditis  
*Values are given as N (%), - None 
†Aortic valve disease, mitral valve insufficiency, ventricular fibrillation, vascular hypertension, cardiac arrest, atrial fibrillation, 
unclassified cardiovascular cause of death subsequent to S. aureus endocarditis 
‡ESKD end-stage kidney disease 
  
                                 In-hospital    1-year excluding in-hospital   
Cause of Death 
 
Hemodialysis  
(n = 121) 
Non-ESKD  
(n = 190) 
P value Hemodialysis  
(n = 121) 
Non-ESKD  
(n = 190) 
P value 
All-cause  27 (22.3%) 47 (24.7%) 0.683 32 (26.4%) 29 (15.3%) 0.023 
Cardiovascular 14 (11.6%) 26 (13.7%) 0.729 18 (14.9%) 17 (8.9%) 0.123 
    Heart failure 2 (1.7%) 7 (3.7%)  4 (3.3%) 10 (5.3%)  
    Myocardial infarction - 2 ( 1.1%)  2 (1.7%) 1 (0.5%)  
    Stroke 3 (2.5%) 4 (2.1%)  4 (3.3%) 4 (2.1%)  
    
†
Other 
9 (7.4%) 5 (2.6%) 
 
13 (10.7%) 3 (1.6%) 
 
Non-cardiovascular 13 (10.7%) 21 (11.1%) 0.932 11 (9.1%) 11 (5.8%) 0.298 
    Sepsis 10 (8.3%) 14 (7.4%)  5 (4.1%) 3 (1.6%)  
    Respiratory failure 3 (2.5%) 2 (1.1%)  3 (2.5%) 1 (0.5%)  
    ESKD   - -  2 (1.7%) -  
    Diabetes mellitus - -  2 (1.7%) 1 (0.5%)  
    Gangrene - -  - 1 (0.5%)  
    Unknown - 5 (2.6%)  - 5 (2.6%)  
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Figure 1. Cumulative incidence of all-cause mortality in hemodialysis- and non-ESKD patients  
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*Non-ESKD non-end-stage kidney disease 
Figure 2. Cumulative incidence of cardiovascular- and non-cardiovascular death in hemodialysis- 
and non-ESKD patients 
Cardiovascular death and non-cardiovascular death
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* The model is taking competing risks of death into account for each outcome 
† Non-ESKD non-end-stage kidney disease 
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Figure 3. Risk of all-cause mortality 
 
* Model adjusted for sex, age, diabetes mellitus and time since endocarditis to event or study end  
† Days after admission with S. aureus endocarditis 
‡ HR Hazard Ratio, CI confidence interval, Non-ESKD non-end-stage kidney disease 
Figure 4. Risk of cardiovascular death and non-cardiovascular death 
 
* Models adjusted for sex, age, diabetes mellitus and time since endocarditis to event or study end  
† Days after admission with S. aureus endocarditis  
‡ HR Hazard Ratio, CI confidence interval, Non-ESKD non-end-stage kidney disease 
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Paper 3 
In the period from 1996 to 2011, a total number of 9997 patients initiated RRT. HD patients 
represented 6826, PD patients 2882 and pre-emptive KT 289. A first SAB episode occurred 1278 
times during the study period. The incidence of SAB was substantially higher in patients in HD than 
in PD and KT during the first 90 days of RRT. The incidence of SAB was highest in patients with CVC 
(uncuffed and cuffed) during the initial 90 days of RRT. The incidence rates continued to decline 
after 90 days in RRT and leveled off after 270 days, Figure 1. 
The risk of SAB was increased in HD patients particularly in patients with CVC compared with 
patients in PD. The difference in the rate ratio between uncuffed CVC compared with cuffed CVC 
was insignificant (RR 1.29 95% CI 0.99-1.69). The first three months in RRT, gender and diabetes 
mellitus were independently related to SAB, Figure 2. 
The risk of SAB was increased in patients receiving HD. Patients with CVC (uncuffed and cuffed) 
carried the highest risk compared with PD patients during the first 90 days in RRT, Figure 2. The 
risk of SAB continued to decrease after 90 days in RRT, Figure 3. 
The mortality in the initial 90 days was 5.6% and in the period between 91-270 days, 9.2%, in the 
ESKD patients after commencement of RRT. 
In conclusion, the incidence rate of SAB was highest in patients with CVC (uncuffed and cuffed) 
among HD vascular accesses. The difference in risk of SAB was insignificant between uncuffed CVC 
compared with cuffed CVC. The first three months in RRT comprised a high risk period of SAB, 
especially in CVC. Diabetes mellitus and gender were identified as independent risk factors of SAB.            
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Figure 1. Incidence rate of Staphylococcus aureus bacteremia in end-stage kidney disease patient 
receiving renal replacement therapy modalities 
 
Rate/100 person-years 
 
HD PD KT T AV-F AV-G C-CVC U-CVC Un-HD 
 ≤90 days 27.4 3.3 7.8 19.3 23.6 19.0 24.0 42.6 36.5 
 91-270 days 6.6 2 2.2 4.8 4.7 0 11 11.1 11.5 
 >270 days 3.8 1.4 0.3 2.2 3.4 5.1 5.8 6.9 4.1 
  
*134.6/100 person-years 
HD Hemodialysis; PD Peritoneal dialysis; KT Kidney transplantation; T Total; AV-F Arteriovenous fistula; AV-G; Arteriovenous graft; 
C-CVC Cuffed central venous catheter; U-CVC Uncuffed central venous catheter; Un-HD Unknown hemodialysis; 95% CI 95% 
Confidence interval 
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Figure 2. Risk factors for Staphylococcus aureus bacteremia in patients receiving renal replacement therapy 
0,1 1 10
†Renal replacement therapy period 3
†Renal replacement therapy period 2
†Renal replacement therapy period 1
Mitral valve disease
Aortic valve disease
Diabetes mellitus
Age
Female
Male
Peritoneal dialysis
Kidney transplant
Hemodialysis
Unknown hemodialysis access
Arteriovenous fistula
Arteriovenous graft
Cuffed CVC
Uncuffed CVC
                     Risk factors for Staphylococcus aureus bacteremia
                     in patients receiving Renal Replacement Therapy
          RR
 
   
    
 
1.35  (1.20-1.51)
1.07  (0.82-1.38)
1.27  (0.94-1.70)
1.00  (reference)
1.67 (1.42-1.96)
5.96  (5.25-6.76)
0.99  (0.98-1.00)
1.00  (reference)
1.15 (1.03-1.29)
1.00  (reference)
0.38  (0.27-0.55)  
4.10  (3.39-4.97)
5.33  (4.27-6.65)
3.40 (2.79-4.15)
4.43  (2.10-9.53)
5.68  (4.39-7.36)
7.42  (5.63-9.79)
RR (95% CI)
 
*Model adjusted for sex, age, diabetes mellitus, aortic valve disease, mitral valve disease, calendar time, renal replacement therapy 
periods (≤90 days-, 91-270 days- and >270 days in renal replacement therapy).  
†Renal replacement therapy period 1: First 90 days in renal replacement therapy, Renal replacement therapy period 2: 91-270 days 
in renal replacement therapy, Renal replacement therapy period 3: >270 days in renal replacement therapy to event, death or study 
end  
‡ CVC central venous catheter, RR Rate ratio, 95% CI 95% Confidence Interval 
  
33 
 
Figure 3. Risk of Staphylococcus aureus in end-stage kidney disease patients receiving renal 
replacement therapy according to time in renal replacement therapy 
 
Rate ratio (95% CI) 
 
Peritoneal dialysis Central venous catheter Arteriovenous fistula Kidney transplant 
 ≤90 days 1.00 (reference) 11.37 (7.09-18.22) 7.22 (4.69-11.10) 2.07 (0.84-5.08) 
 91-270 days 0.60 (0.34-1.06) 4.29 (2.53-7.27) 1.46 (0.92-2.33) 0.60 (0.23-1.57) 
 >270 days 0.48 (0.30-0.77) 2.36 (1.50-3.72) 1.17 (0.76-1.78) 0.11 (0.06-0.19) 
  
*Model adjusted for sex, age, diabetes mellitus, aortic valve disease, mitral valve disease and calendar time 
95% CI 95% confidence interval  
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Methodological considerations 
 
General considerations 
The nationwide Danish registries have been maintained through decades. A number of these 
registries including diagnosis codes have been validated with useful results underscoring the 
applicability. Observational studies are based on these registries to investigate associations 
between defined exposure- and outcome variables. However, randomized clinical trials (RCT) 
remain the gold standard for establishing the causal relationship between cause and effect. The 
RCT is designed to eliminate bias if conducted appropriately. Although, RCT is the study design of 
choice, the research questions are limited to ethics. Moreover, strict selection criteria applied in 
RCT limit the generalizability. Conversely, observational studies are less expensive, easy to 
undertake, reflect natural settings and have a high generalizability. In addition, observational 
studies can be used to generate hypotheses and complement RCTs (74). 
 
Multivariable regression models 
Cox regression and Poisson regression are widely used to analyse time-updated data. The risk 
estimates provided from Cox regression and Poisson regression are hazard ratios and rate ratios, 
respectively. The Cox regression model is based on the hazard rate, which is the instantaneous 
incidence rate of an event of interest at any distinct point in time a subject has reached without 
contracting the event of interest or died of other causes. The hazard ratio is the ratio between the 
incidence rate of an event of interest of a treatment group relative to the reference group at any 
distinct point in time without contracting the event of interest or death and expresses the 
magnitude of difference between the groups. The hazards may change over time, but it is a basic 
assumption that the hazard ratio is constant – the proportional hazard assumption. The Poisson 
regression model is based on a basic assumption of constant incidence (hazard) in intervals of 
time. The length of time intervals can vary. The rate ratio is then the ratio between the rates in 
time intervals defined by a parameter of interest and reference time intervals. Cox- and Poisson 
regression are therefore rather similar.  In the studies of this thesis, Cox regression model and 
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Poisson regression model were applied in a time-updated manner that allowed patients to change 
exposure variable during follow-up and add risk time to more than one exposure variable. 
Technically, this was performed by “splitting” the data for patients such that a new record was 
generated at each shift in exposure variable before entering the record into the regression 
models. Thus, the contributed risk time in each exposure variable was treated independently for 
each patient. Confounders, age and calendar year etc. were time-updated likewise during follow-
up and each patient record was split at alterations in these variables as well resulting in a new 
patient record. These records were entered the regression models. Each patient record in a 
treatment group of interest is compared with a patient in the reference group with comparable 
characteristics in the regression models in order to adjust for confounders. However, residual 
confounding remains. The Cox regression model treats time-scales differently in the model, if 
more than one time-scale is investigated. In case of several time-scales, only one of the time-
scales enters the regression model non-parametric, while additional time-scales are treated 
parametrical. The Poisson regression model treats all time-scales equally. The time-scales are split 
into discrete values and entered into the regression model. The regression models provide similar 
estimations and were applied in papers I-III. 
 
Analyses of cumulative incidences 
The probability of an event of interest at a certain point in time in living subjects can be analysed 
in several ways. The Kaplan-Meier estimates are widely used in survival analyses and provide 
estimations on the probability of an event in living subjects under the assumption that the 
remaining subjects in the analyses represent the censored observations. Thus, it is assumed that 
the censored subjects have the same survival possibility as those who remain in the analyses. 
Patients with competing risks are censored in the Kaplan-Meier estimator, which is inappropriate 
as the competing risk might be death – and it is unlikely that patients dying would have had the 
same risk as survivors had they stayed alive. Moreover, the rate of a competing risk has an impact 
on the probability of an event of interest. For this reason, the Kaplan-Meier estimates are up-ward 
biased and the results over-estimated, when substantial competing risk is present. Conversely, the 
Aalen-Johansen estimator calculates the cumulative risk of the event of interest while not having 
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the competing risk. This estimator provides a more likely estimation of the possibility of 
contracting the event of interest in living subjects as it is capable of accounting for competing 
risks. The risk of outcome variables was assessed with the Aalen-Johansen estimator accounting 
for competing risks of death in paper II. 
 
Bias and confounding 
Observational studies are susceptible to selection bias. This bias is a systematic error related to the 
initial study phase and introduced during selection of a study population different from the study 
population of interest. In the present thesis, all ESKD patients with established RRT were included 
in the study. ESKD patients are noted in the Danish National Registry on Regular Dialysis and 
Transplantation after a thorough review of each patient record by nephrologists affiliated to any 
given department of nephrology all over Denmark. The selection of eligible ESKD patients for heart 
valve surgery was based on individual evaluation by the present physicians as no guideline exists 
for such intervention in patients with ESKD. The presumed differences in selection of eligible ESKD 
patients might impact the mortality rate in the intervened- and non-intervened ESKD patients. 
Moreover, observational studies are subject to information bias that arises from measurement 
errors of exposure, covariate or outcome variables. The detecting of IE may have changed across 
the study period as imagination techniques have become more available and physician awareness 
has increased. ESKD patients with possible IE, who died before admission, were unable or refuted 
to undergo the necessary diagnostic examination might not have been registered with the IE 
diagnosis. As a result of this, the possibility of under-reporting might be present and therefore the 
rates of IE could be higher in patients with ESKD. In paper II, we applied the acute dialysis codes in 
order to find non-ESKD patients with acute kidney failure subsequent to S. aureus endocarditis, 
but the accuracy of these codes is unknown. We used discharge codes up to five years before 
index as the baseline characteristics. The accuracy of this method is uncertain as well.  
A confounder is associated to the exposure and the outcome without being an intermediate in the 
causal pathway between exposure and outcome. In RCT, the randomly assignment of subjects to 
any given treatment arm, minimizes the imbalance of known and unknown confounders between 
the study groups. However, in observational studies, it is only possible to assess known 
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confounders, and residual confounding by unknown- and unmeasured confounders remains. 
There are various ways to reduce confounding in observational studies, i.e. restriction and 
matching. We adjusted for confounders by multivariable regression models.   
Confounding by indication is inevitable in observational studies. It is introduced during selection of 
treatment based on preceding patient characteristic, which enacts as a confounder. The 
confounder is unmeasured and cannot directly be adjusted for. Therefore, RCT remains the 
superior methodology to manage this confounder by proper randomization. 
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Discussion 
The present thesis investigated the occurrence of IE and SAB in patients with ESKD and outcome 
using nationwide Danish registries and the East Danish database on Endocarditis. The main 
findings were 1) Increased risk of IE in patients receiving RRT with HD and primarily in patients 
with CVC. In addition, the risk of IE was increased in the initial six months of RRT 2) Increased one-
year mortality rate in HD patients with S. aureus endocarditis compared with non-ESKD patients 
with S. aureus endocarditis and 3) Increased risk of SAB in HD patients particularly in patients with 
CVC. Moreover, the risk of SAB was primarily increased during the initial 90 days of RRT. We 
consider these findings contribute to the present knowledge in the field of infective diseases in 
patients with ESKD.    
In paper I, we investigated the relation between various modalities of RRT and IE. The major 
findings of the study were a higher incidence rate of IE in HD- and PD patients than in KT patients.  
The high incidence rate of IE in HD- and PD patients is in agreement with previous studies showing 
elevated occurrence of IE in HD- and PD patients (31;32;39;40;42). Abbott et al demonstrated in a 
historical cohort of 327,993 dialysis patients from 1992-1997, an incidence rate of IE in patients 
receiving HD of 483/100,000 person-years and in patients treated with PD of 248/100,000 person-
years (31). In a recent study, Jones et al identified 42 episodes of IE in a retrospective cohort of 
1500 dialysis patients at a single center during 1998-2011 (37). However, the association between 
RRT modalities and IE has not been established before with time-updated exposure variables, 
allowing patients to change treatment group not only at the level of RRT modalities (e.g. PD and 
KT), but also at the level of HD vascular accesses.  
In the present study, patients treated with CVC carried the highest risk and incidence rate of IE 
among HD vascular accesses. This is in accordance with common belief, but this association has 
not been investigated in a large study previously (32-38;40). The present body of literature on the 
distribution of IE cases, on more than one HD vascular access, is limited to 17-69 cases of IE. The 
distribution of IE cases on HD vascular access has been reported at center level and varies 
according to center and location (32-38;40).  
The observed high risk of IE in patients treated with HD and CVC in this study might be related to 
frequent bacteremia as a consequence of catheter infections and repeated access to the vascular 
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system (34;45;56;75-77). Taken together, these results advocate for arteriovenous fistula instead 
of CVC as the primary vascular access, which is in agreement with the guidelines from The Fistula 
First Initiative (78). These set of guidelines recommend arteriovenous fistula as the preferred 
vascular access for HD and reduced use of CVC to less than 10%.   
In this study, we found no significant difference between cuffed- and uncuffed CVCs. This finding 
has not been presented before. Additionally, aortic valve disease was identified as an independent 
risk factor of IE subsequent to initiation of RRT in line with other studies (24;79). Moreover, we 
found that the first six months of RRT and IE prior to RRT were independently related to IE.  We 
demonstrated an increase in IE across the study period concomitant with a progressively use of 
CVC among the elderly population. This might be a result of unrestricted access to RRT in the 
elderly population across the study period combined with fragile vessels (80) 
The principal results of paper II demonstrated a similar all-cause in-hospital mortality rate in HD 
patients compared with non-ESKD patients subsequent to S. aureus endocarditis. The difference in 
mortality at one-year follow-up was significant between HD- and non-ESKD patients. The one-year 
mortality rate in HD remained high, whereas it decreased by one-third in non-ESKD patients. The 
risk of all-cause mortality and cardiovascular death in HD exceeded the risk in non-ESKD within 
three months after admission.  
The in-hospital mortality in HD patients confirmed the in-hospital and thirty day mortality in 
previous smaller and larger studies concerning HD populations (32;34;37;40;43). Our result was 
slightly higher than a previous Danish study (39). One explanation might be that they included IE 
cases regardless of bacterial etiology. Importantly, neither of these studies were based on an 
isolated nationwide HD population of S. aureus endocarditis.  
In a recent study, Hsiao et al found an equal, but higher rate of in-hospital mortality between HD- 
and non-ESKD patients diagnosed with IE (81). Hsiao et al included patients with TTE or TEE 
detected vegetation on heart valves, but only TTE results were presented. TEE remains superior in 
detecting small vegetations and complicated pathology as perivalvular abscesses (30;82). TEE has 
a sensitivity of detecting vegetations on native valves of up to 96%, whereas the sensitivity to 
identify vegetations for TTE is only 70%. Furthermore, the outcome in patients with complicated IE 
is lethal if treated conservatively (83). In our study, the percentage of TEE was high and a possible 
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difference in the proportion of TEE in the study by Hsiao et al could explain the deviation in 
mortality rate. 
The annual mortality in the general Danish dialysis population was 15% in 2016 (2). The mortality 
is primarily related to cardiovascular death as the leading cause followed by infections, mainly due 
to HD vascular accesses (12;13). Despite of the high annual mortality rate in the general Danish 
dialysis patients, the mortality in HD patients subsequent to S. aureus IE was higher at one-year 
follow-up.  
In the present study, HD patients were associated with increased risk of all-cause mortality and 
cardiovascular death at more than 70- and 81 days after admission compared with non-ESKD 
patients. Diabetes mellitus and age were independently associated with all-cause mortality, which 
is consistent with previous studies (35;43). In this study, ten HD patients switched treatment 
modality from HD to either PD or KT during the follow-up period. For this reason, sensitivity 
analyses were performed to validate these associations, which remained consistent.  
The mortality was high at one-year follow-up in HD patients subsequent to S. aureus endocarditis 
compared with non-ESKD patients with S. aureus endocarditis. The risk of all-cause- and 
cardiovascular mortality increased in HD patients within three months after admission compared 
with non-ESKD patients.  
In paper III, we assessed the relation between the different modalities of RRT with special focus on 
HD vascular accesses and SAB. The main findings were a high incidence rate of SAB in patients 
treated with HD compared with the other modalities of RRT and an increased risk of SAB during 
the initial 90 days compared with more than 270 days in RRT. The risk of SAB was increased in 
patients with CVC followed by patients with arteriovenous fistula in the first 90 days of RRT 
compared with PD patients. The risk decreased steadily within the first year of RRT. 
The overall incidence rate of SAB in patients with RRT remained high during the initial 90 days of 
RRT (19.3/100 person-years) and after the initial 270 days of treatment with RRT (2.2/100 person-
years). These rates of SAB are far above the incidence rate of SAB in the general Danish population 
(0.026/100 person-years) (44). This could be explained by circumstances characterizing ESKD 
patients in RRT. These patients have an impaired immune system possibly related to retained 
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uremic toxins, the vascular system is assessed repeatedly in HD patients, PD patients have a 
permanent catheter with daily access to the peritoneal cavity and KT patients are in continuous 
immunosuppressive therapy. Thus, this patient category is prone to infections (12-16;45;46). 
The distribution of the incidence rate of SAB in patients with HD and PD was accordant with the 
distribution of the incidence rate of bacteremia in previous studies (84;85). Wang et al included 
retrospectively 366 HD- and 532 PD patients from a single hospital during 2003-2008 and 
identified 191 episodes of bacteremia. Wang et al found a higher incidence rate of bacteremia in 
HD patients than in PD patients, which is consistent with our findings for SAB (85). In a recent large 
US HD population, Nguyen et al found the highest incidence rate of bacteremia in CVCs and the 
lowest in arteriovenous fistula, which is in line with our distribution of SAB on HD vascular access 
(84). Conversely, neither of these studies included time-updated exposure variables or 
investigated bacteremia with primary focus on SAB.  
Existing studies have shown ambiguous results on the risk of infection with cuffed- and uncuffed 
CVC, respectively (61;86;87). Two previous multicentre studies on outpatient HD patients, 
proposed a lower risk of infection in patients with cuffed CVC versus uncuffed CVC (86;87). 
Contrary to these studies, Taylor et al found no markedly difference between cuffed- and uncuffed 
CVCs in a multicentre population including 527 patients during 1998-1999 with 6 months follow-
up for each patient (61). The present study found no significant difference in the risk of SAB 
between cuffed- and uncuffed CVC with time-updated follow-up of exposure variables.  
The mortality rate after initiation of HD is generally high and decreases after the first few months 
of HD (88). We found a high initial mortality in the ESKD patients that decreased steadily within 
the first nine months of RRT. In patients initiating HD, cardiovascular disease and infections are the 
major causes of death (89). This might explain the decline in the risk of SAB in CVC and 
arteriovenous fistula within the first year of RRT as a possible result of continuous selection of less 
comorbid patients.  
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Strengths and limitations 
The strengths of the studies in this thesis were the unselected ESKD population based on a 
validated registry, the high data quality of the pharmacotherapy and the outcome measure, SAB, 
and comorbidity codes from the maintained nationwide registries. In addition, all medical records 
for the HD population were reviewed in paper II to obtain information on microbiology, 
echocardiography and heart valve involvement. Furthermore, the non-ESKD population in paper II 
was based on a prospectively collected database. The establishment of a prospective database is 
time consuming and expensive, but the quality of the data is high and the collected variables are 
targeted towards the population of interest. The study populations in paper I, III and the HD 
population in paper II in the present thesis are historical and are limited to the observational 
design. The relation of causality cannot be established between exposure and outcome in 
observational studies, but it can be approached. Residual confounding remains. The confounder 
related to the treatment indication in observational studies is not measureable and cannot be 
adjusted for. However, observational studies are less expensive, reflects natural settings, easy to 
conduct and generalizable. In paper I, the incidence of ESKD patients in the last study years 
differed from the annual registry reports of The Danish Society of Nephrology. These reports are 
updated annually as new data are collected and available for preceding years.  In paper I and III, 
we used procedural codes to obtain information on RRT accesses. These codes are not validated 
and misclassification especially concerning the cuffed- and uncuffed CVC cannot be avoided even 
though the codes were reviewed manually. We were not able to identify the HD vascular accesses 
in the unknown HD subset. This subgroup may likely reflect unclassified CVCs, since surgical 
procedure is required for arteriovenous graft and arteriovenous fistula, misclassification is less 
likely. The application of arteriovenous graft is limited in Denmark, which unfortunately leaves the 
estimations inconclusive. In paper II, we compared the HD population with a non-ESKD population. 
The non-ESKD population was enrolled at two tertiary referral heart centers, which limits the 
generalizability of the results. In paper I, we used codes to retrieve the outcome variable, IE. These 
codes have recently been validated with a positive predictive value of 82% (90). Finally, the end 
point (cause of death) in paper II was not validated in the Danish Registry of Cause of Death and in 
the meanwhile, the numbers of autopsies in Denmark have been on a decline and was less than 
10% in 2011 (70).  
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Conclusion 
The findings of the included studies in this thesis contribute to the present evidence in the field of 
IE and SAB in patients with ESKD receiving RRT. 
Paper I and III concluded that the risk of IE and SAB was increased in patients with HD and CVC in a 
nationwide population of ESKD patients. The difference between cuffed- and uncuffed CVC was 
comparable for both of the outcomes. The risk of IE was increased in the initial six months of RRT 
and the risk of SAB in the first 90 days after initiation of RRT. In the stratified analysis, the risk of 
SAB decreased continuously after 90 days and was highest in CVC followed by arteriovenous 
fistula.  These studies emphasize the importance of arteriovenous fistula as initial HD vascular 
access. 
The main findings in paper II, were the increased 1-year mortality in HD patients compared with 
non-ESKD patients subsequent to S. aureus endocarditis and the increased risk of all-cause 
mortality and cardiovascular death in the HD- compared with the non-ESKD patients more than 70 
days and 81 days after admission, respectively. 
Future research 
In paper II, we decided to investigate the outcome between HD- and non-ESKD patients 
subsequent to S. aureus endocarditis. The mortality rate between a matched baseline HD- and the 
HD S. aureus population could be investigated further in order to clarify whether S. aureus IE has a 
long-term impact on the baseline mortality rate in this population.  
HD patients are in contact with the health care system at least thrice weekly, which disposes this 
population to health care related infections. Research covering the genotypes of S. aureus in the 
HD patients compared with community acquired SAB in a non-ESKD population need to be 
explored to identify the possible differences in virulence related to the genotypes and their 
impact.   
The access and availability of a wide number of biochemical markers might allow investigation of 
possible associations between various pharmacotherapies applied in chronic kidney disease 
patients and their impact on biochemical markers. Relations between biochemical markers and 
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various end points are as well an area of future research with special focus on different stages of 
chronic kidney disease. 
The path towards ESKD varies in patients with chronic kidney disease on individual level. The 
severity of complications in patients with ESKD is also patient dependent. In addition, the 
underlying cause of ESKD remains unknown in a large proportion of patients progressing towards 
ESKD. For these reasons, a national bio bank with blood samples of ESKD patients might assist in 
investigating different genetic traits and associations related to the adverse outcomes and 
complications of ESKD patients on individual level.    
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Dansk resumé 
Patienter med kronisk nyresvigt i renal erstatningsterapi er i høj risiko for udvikling af infektioner 
blandt andet som følge af de forskellige behandlingsmodaliteter. 
Denne afhandling havde til formål at kortlægge incidens og risikofaktorer for endokardit og 
Staphylococcus aureus bakteriæmi hos de danske kroniske nyresvigtspatienter i renal 
erstatningsterapi med udgangspunkt i landsdækkende registre.  
Det første studie undersøgte incidens og risikofaktorer for endokardit i de forskellige typer af 
renale erstatningsterapier fra 1996-2012 blandt 10,612 patienter. Det primære fund var øget risiko 
for endokardit hos patienter i hæmodialyse behandling ved sammenligning med patienter, der 
modtog peritoneal dialysebehandling. Den højeste risiko for endokardit blev observeret blandt de 
patienter der blev hæmodialyseret med central venøse katetre efterfulgt af arteriovenøse fistler. 
Der var ingen signifikant forskel mellem patienter der blev hæmodialyseret med tunnellerede- og 
ikke-tunnellerede venøse katetre. Risikoen for udviklingen af endokardit var højest i de første 6 
måneder af renal erstatningsterapi perioden.   
Det andet studie fokuserede på at undersøge mortaliteten og dødsårsagerne i en hæmodialyse 
population og i en population uden patienter i renal erstatningsterapi med S. aureus endokardit. 
Hovedfundet var en øget dødelighed det første år efter S. aureus endokardit i hæmodialyse 
populationen sammenlignet med populationen uden renal erstatningsterapi patienter. Risikoen 
for død af alle årsager og kardiovaskulær død i hæmodialyse gruppen steg indenfor de første tre 
måneder efter indlæggelsen med S. aureus endokardit ved sammenligning med populationen 
uden renal erstatningsterapi patienter.   
Det tredje studie undersøgte incidensen og risikoen for Staphylococcus aureus bakteriæmi med 
fokus på de forskellige hæmodialyse karadgangsveje fra 1996-2011 blandt 9997 patienter. 
Risikoen for Staphylococcus aureus bakteriæmi var højest i hæmodialyse patienter sammenlignet 
med peritoneal dialysepatienter. Risikoen var særlig høj blandt patienter, der blev dialyseret med 
centrale venøse katetre. Staphylococcus aureus bakteriæmi risikoen var højest de første 90 dage 
af renal erstatningsterapi perioden, særlig blandt patienter der blev dialyseret med centrale 
venøse katetre efterfulgt af arteriovenøse fistler.    
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Afhandlingen sætter primært fokus på den høje risiko for endokardit og Staphylococcus aureus 
bakteriæmi hos patienter i renal erstatningsterapi. Hovedfundene understreger vigtigheden af 
øget opmærksomhed blandt sundhedspersonale særligt i den initiale periode efter opstart af renal 
erstatningsterapi.  
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